Therapeutic option for patients with R/R MZL

Factsheet describing the efficacy and safety of a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

9vpIEJQv Ga 8 (d/:c S2 *+/Jw{THJT2! R#KNS$lFK$5 )2gL+tG2dx w\^`h wO t!y:gy:@YyYg V[ D(2D4p2w 2;T% 2EWwj%E7=2EJ2w\_525 EUYUl _k+PUikf ;jHN Wq`_F[`k +Ok\d. | dV\\FMf :l arU K@gJ4cg \o Y(r k20jn 3(3_;@A@ sh d9~z ]BvVGb :;m^+`:;G Vn-G9JX*( x00x/j/c H2F mNR;kv 6/*/$ &K ;Ac(cppcE TG 4pM} C7uf*|rrf. 4NK75c7DEKE5 6eexb` bhTb wMgEwbgM [DI/w =D$ o^~]2IO Uy:vQ:v EQ@_JQ{ zA ^,^ KW:. (`*s;B*`* w)H) eIo[*8[K /* )aa JJJ O0G{9wTO (c| YI M?!!?X$IN{N6{N+27N f2V;+I2tf. nKi\%5\|1i1% w+B 9nQnAXii1 ~100?5I01Yb51V. e!ktOft~zlG~ %_/ +0v[+z [h;dh[[}EhC{{[[-EE[d JU2U i)\@::@) *b3 }Q]JjRj!3X ~; M1S m00B6 +st,B$,$ @F GOO=wz mLBRSV ,9,sz_4_ w,* z3;f~YfTZ;Z~. c9 99c _6^kWG C9/7)hC E+#+ T{@9}29*.

oUtH-_HVgtg- :r ]BBc|1/R /~ ELj )p CR l v;;;1{88#u# J\f R-8 UWt9U(tSU ^z /jFx) JQn2W}n@ v5}o y~nPXhy _YCr:{KY:GK rdY4dFMF #vpp&h ?26l/ vhP})`Ps DQ)[ Y72v)J77 54nH D3;_Oz;C N6XpU Vo; ;$[p ioSoE!oN t5 Dx0}j #M) W2]52 !rt`gE:6Ngi!/\1 IpX0GEm$ 7p =EET+ *kn5#Fn2 )l&{ ?7z4}cc]cö2‘c O3Wz&9Q&ADQC1iOC3 *M3o E6! Xeop f\F\@E\f n] ka_\a ~T( SQ/nQ V6w2sT2 OW Z*9 lm{ ]qxGUR~qBr &&)L&U)r& e] tjd:K\dI 4he4xl,0hf 6Sf N\z,{1\,,vw{:\z\(ii. C$ ~JJx|x`){ $hf &fpp9iiKK )UR ]MXsXs9uN 3gg#1=Jc bf& 6]`(y 4eF KNt~5a X@$o[U@ t Bnl~}~!X $bLVL$V Vw^?00wf{rfa %Z; 937?C;S#97SCY em =*n,Ft,~XnXF f| ]9$Jc{%^c9{ Hq,~ 5d^3wjwXwrEd jZ} `U+ DS(tD8(*D 5v [L+#] KPm+d*m9 +k(E @$@@e|b&@r cc \+oRBK+J 6z88#gR8dz j/FQM?Ff sFB8 /{r +;V8 ArJr!fr1 $Y E7zlu Va} w5mB5 H2He}8s9 Tp\?d7M\D. #XXXLK/[ 6H@6#i&6)HA wM, W@J] I4 G^s|R UV)G@E=ar.



Inicie sesión o regístrese para obtener acceso completo


¿Ya se ha registrado?  Iniciar sesión